3d printing of biomedical implants

Abstract

Provided herein are methods, compositions, devices, and systems for the 3D printing of biomedical implants. In particular, methods and systems are provided for 3D printing of biomedical devices (e.g., endovascular stents) using photo-curable biomaterial inks (e.g., or methacrylated poly(diol citrate)).

1 . A system comprising:
 (a) a photo-curable biomaterial ink; and   (b) a 3D printing device for:
 (i) dispensing a layer of the photo-curable biomaterial ink in a pattern according to encoded instructions, 
 (ii) exposing the layer of the photo-curable biomaterial ink to light to cure the biomaterial ink and produce a solidified biomaterial layer, and 
 (iii) repeating steps (i) and (ii), with each successive layer built upon the previous layer to produce a 3D structure of the solidified biomaterial. 
   
     
     
         2 . The system of  claim 1 , wherein the photo-curable biomaterial ink comprises methacrylated poly(diol citrate). 
     
     
         3 . The system of  claim 1 , wherein the poly(diol citrate) comprises a polymer of citric acid and HO—(CH 2 ) n —OH, wherein n is 2-20. 
     
     
         4 . The system of  claim 1 , wherein the photo-curable biomaterial ink further comprises one or more of: a solvent, a photoinitiator, a co-initiator, a free-radical quencher, and a UV-absorber. 
     
     
         5 . The system of  claim 1 , wherein the 3d printing device is configured for laser scanning stereolithography, projection stereolithography, ink-jet printing, continuous liquid interface production, or combinations thereof. 
     
     
         6 . A biomaterial device produced using a system of one or  claims 1 - 5 . 
     
     
         7 . A biomaterial ink comprising methacrylated poly (diol citrate), solvent or dilutant, and a photoinitiator. 
     
     
         8 . The biomaterial ink of  claim 7 , wherein the poly (diol citrate) is a polymer of citric acid and an aliphatic diol selected from selected from HO—(CH 2 ) n —OH, wherein n is 2-20. 
     
     
         9 . The biomaterial ink of  claim 7 , wherein the methacrylated poly (diol citrate) is present in the biomaterial ink at 50-99 wt %. 
     
     
         10 . The biomaterial ink of  claim 7 , wherein the solvent or dilutant is present in the biomaterial ink at 1-49.9 wt %. 
     
     
         11 . The biomaterial ink of  claim 7 , wherein the photoinitiator is present in the biomaterial ink at 0.1-5 wt %. 
     
     
         12 . The biomaterial ink of  claim 7 , further comprising a co-initiator, a free-radical quencher, and/or a UV-absorber. 
     
     
         13 . The biomaterial ink of  claim 7 , further comprising a radiopacity agent. 
     
     
         14 . The biomaterial ink of  claim 13 , wherein the radiopacity agent is selected from the group consisting of: iohexyl, iopromide, ioversol, ioxaglate and iodixanol 
     
     
         15 . The biomaterial ink of  claim 7 , further comprising a therapeutic agent. 
     
     
         16 . The biomaterial ink of  claim 15 , wherein the therapeutic agent is selected from the group consisting of: anticoagulants, antithrombotic agents, antiplatelet agents, anti-inflammatory agents, anti-proliferative agents, immunosuppresive agents, cytostatic drugs, lipid-lowering agents, and antioxidants. 
     
     
         17 . A biomaterial device produced by the curing of a biomaterial ink of one of  claims 7 - 16 .